ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

Source: 
Fierce Pharma
snippet: 

Two cancers studies are slated to grab significant attention at the upcoming American Society of Clinical Oncology 2023 annual meeting, and each could lead to a major label expansion for the companies involved.